A Multicenter Study of Avapritinib Efficacy and Safety of Metastatic or Unresectable Gastrointestinal Stromal Tumors
NCT05464875 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 74
Last updated 2025-02-26
Summary
This is a prospective, multicenter, observational real-world study to explore the therapy patterns and clinical outcomes of Avapritinib in patients with metastatic or unresectable gastrointestinal stromal tumors.
Conditions
- Gastrointestinal Stromal Tumors
- Unresectable Solid Tumor
- Recurrent Metastatic Malignant Neoplasm
Sponsors & Collaborators
-
Peking University Cancer Hospital & Institute
collaborator OTHER -
Fudan University
collaborator OTHER -
Peking University People's Hospital
collaborator OTHER -
Chinese PLA General Hospital
collaborator OTHER -
Xiangya Hospital of Central South University
collaborator OTHER -
Peking University Shenzhen Hospital
collaborator OTHER -
Nanfang Hospital, Southern Medical University
collaborator OTHER -
West China Hospital
collaborator OTHER -
Jiangsu Cancer Institute & Hospital
collaborator OTHER -
Shanghai Zhongshan Hospital
collaborator OTHER -
Sun Yat-sen University
collaborator OTHER -
Xijing Hospital
collaborator OTHER -
Shengjing Hospital
collaborator OTHER -
Shanghai Jiao Tong University School of Medicine
collaborator OTHER -
Liaoning Cancer Hospital & Institute
collaborator OTHER -
Sixth Affiliated Hospital, Sun Yat-sen University
collaborator OTHER -
Fujian Medical University Union Hospital
collaborator OTHER -
Cancer Hospital of Guangxi Medical University
collaborator OTHER -
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
collaborator OTHER -
First Affiliated Hospital of Chongqing Medical University
collaborator OTHER -
Chongqing University Cancer Hospital
collaborator OTHER -
Xinhua Zhang, MD
lead OTHER
Principal Investigators
-
Xinhua Zhang, PhD · First affiliated hosptial,Sun Yat-sen university
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-07-09
- Primary Completion
- 2025-12-31
- Completion
- 2025-12-31
Countries
- China
Study Locations
More Related Trials
-
Apatinib as Maintenance Therapy After First Line Treatment in Locally Advanced or Metastatic Gastric Cancer
NCT02537171 ·Status: UNKNOWN ·Phase: PHASE3
-
Apatinib Combined With Paclitaxol as Second Line Therapy for Advanced Gastric Cancer.
NCT03144843 ·Status: UNKNOWN ·Phase: PHASE2
-
PD-1 Antibody + Apatinib Mesylate in 2+ Line Serum AFP-elevated Gastric Adenocarcinoma
NCT04006821 ·Status: UNKNOWN ·Phase: PHASE2
-
Phase III Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer
NCT01512745 ·Status: COMPLETED ·Phase: PHASE3
-
Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer
NCT03219593 ·Status: UNKNOWN ·Phase: PHASE2
-
Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric Cancer
NCT05342389 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of Apatinib Mesylate (YN968D1) 1,000mg in Gastric Cancer Patient Failed to Standard Treatment
NCT02711969 ·Status: COMPLETED ·Phase: PHASE1
-
An Open Label, Prospective, Multicentre, Non-interventional Study of Apatinib for Chemotherapy-Refractory Advanced Metastatic Gastric Cancer
NCT02668380 ·Status: UNKNOWN
-
Apatinib Plus Irinotecan as Second-line Treatment in AGC or EGJA
NCT03116555 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study of Apatinib Combined With S1 in Patients With Advanced Gastric Cancer
NCT03271073 ·Status: UNKNOWN ·Phase: PHASE2
-
Apatinib as Maintenance Therapy After Adjuvant Chemotherapy in Progressive Gastric Cancer With Positive Exfoliative Cancer Cells
NCT02510469 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
The Study of Apatinib Plus CIK as the Third Line Therapy for Patients With Advanced Gastric Cancer
NCT02485015 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Clinical Study on Treatment of Apatinib Mesylate in First-line Maintenance of Advanced Gastric Cancer
NCT03255811 ·Status: UNKNOWN ·Phase: NA
-
Apatinib for the Elderly Advanced Gastric Cancer
NCT03104283 ·Status: COMPLETED ·Phase: PHASE2
-
Relationship Between Standard Treatment Efficacy and The Tumor Microenvironment in Advanced Gastric Cancer
NCT04850716 ·Status: UNKNOWN
-
Apatinib as Maintenance Therapy After First-line Chemotherapy(DC for 4 Cycles) in Postoperative Recurrence/Metastasis Progressive Gastric Cancer
NCT02509806 ·Status: UNKNOWN ·Phase: PHASE2/PHASE3
-
Apatinib Versus Placebo as a Third Line Treatment in Patients With Advanced or Metastatic Gastric Cancer
NCT00970138 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed
NCT06885034 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Apatinib Combined With Capecitabine Second-line Treatment of Advanced Gastric Cancer: a Single-arm Exploratory Clinical Pilot Trial
NCT03531931 ·Status: UNKNOWN
-
The Real World Study of Apatinib for Gastric Cancer Treatment in Henan Province
NCT03478943 ·Status: UNKNOWN
-
A Study of Apatinib Tablets in the Treatment of Advanced or Metastatic Gastric Cancer
NCT02426034 ·Status: COMPLETED ·Phase: PHASE4
-
Fruquintinib Combined With Toripalimab and SOX Regimen in the First-line Treatment of Advanced Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
NCT05024812 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
The Clinical Research of Mesylate Apatinib Combined With Docetaxel and S-1 as the First-line Treatment of Metastatic Gastric Cancer
NCT03154983 ·Status: UNKNOWN ·Phase: PHASE2
-
Chemotherapy Combined With Apatinib and PD-1 Antibody
NCT05025033 ·Status: COMPLETED ·Phase: PHASE2
-
Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
NCT04609176 ·Status: UNKNOWN ·Phase: PHASE2